Tag Archives: Germany

University of Freiburg spin-off with strong preclinical evidence for significant breakthrough in curing prostate cancer

FREIBURG, Germany, 1-Jul-2021 — /EPR HEALTHCARE NEWS/ — Prostate cancer is the second most common cancer. According to the American Cancer Association, 1 in every 8 men will be diagnosed with it in their lifetime. In 2018 around 1.2 million men were diagnosed and there were 360,000 deaths. In Europe alone, 450,000 men are diagnosed with prostate cancer every year. But there could be a cure on the horizon.

B66, a new company in Germany and a spin-off from the University of Freiburg, Germany, has strong preclinical evidence that its research has made a significant breakthrough after 6 years of dedicated work. Professors Roland Schule, Manfred Jung and Dr Eric Metzger have pioneered research into inhibitors of the histone methyltransferase KMT9 that controls the growth of castration and enzalutamide resistant prostate tumours. These small molecular inhibitors are superior to current state-of-the-art Gold Standard drugs in preclinical models. This new treatment has the prospect of increasing survival in the normally fatal outcome of castration-resistant prostate cancer and becoming the universal therapeutic agent. In addition, the research team’s work shows that their new therapeutic agent has potentials in other cancers including colorectal, breast, bladder and the biggest of all killers, lung cancer.

Professor Roland Schule, one of the B66 founders, and a professor of Biochemistry in the University Medical Centre of Freiburg said “Our findings and approach to treatment is far in advance of anything that is going on in the world at the moment.”

Fellow founder, Professor Manfred Jung, added “many cancer treatments cause damage to the patient’s normal cells but the B66 inhibitor does not target normal cells indicating that our treatment will have minimum side effects”.

Although focused on prostate cancer right now, the B66 team’s long-term objective is to create a world-class development platform that will work on the defeat of many other types of cancer. The Freiburg region, thanks to the University, is a unique centre of leading medical knowledge. B66 will expand their work and draw in some of the skilled scientists from the area to help them work towards building a leading medical development hub.

The B66 team is already seeking commercial partners in order to forward their breakthrough work and advance as quickly as possible to defeat this major cancer.

SOURCE: EuropaWire

The U.S. Department Of Commerce Selects Medelita To Exhibit At Medica 2009

Medelita®, maker of breakthrough scrubs and lab coats for female clinicians, today announced that it has been selected by the United States Department of Commerce to participate in Medica 2009, a leading international trade fair for the medical industry, which will be held in Dusseldorf, Germany, November 18-21. Medica 2009 is comprised of more than 135,000 individuals, representing over 100 countries, that come to learn about current and future trends in both in-patient and out-patient care.

medelita

“As the largest medical trade show of its kind, Medica 2009 is the ideal venue for us to launch a new product line and showcase current Medelita products to an international audience,” said Joe Francisco, chief operating officer, Medelita. “We are extremely pleased to have been selected as one of an esteemed group of companies, to attend this year and showcase our unique lab coats and scrubs.”

Medelita is one of only ten U.S.-based medical supply companies invited to attend Medica 2009 and exhibit with the U.S. Department of Commerce, Office of Textiles and Apparel (OTEXA). In a recent statement, OTEXA reports that the medical textiles segment of the medical sector is experiencing one of the highest expansion rates in the technical textile market. According to recent research, over the next few years the world market for technical textiles and industrial nonwovens will increase by 3.8% per year – a volume value of nearly $126 billion.

In a bid to capture its share of this growing market, Medelita will be exhibiting its innovative medical apparel at the OTEXA USA Sample Pavilion. The company plans to introduce its men’s line of lab coats at Medica 2009. Medelita products are available direct to consumers and through its retail channels. Wholesale orders also are available to hospitals and large groups.

Made f r o m 100 percent high-denier cotton, the Medelita lab coat is designed specifically for women with a focus on fit and function. The fluid resistant lab coats are treated with Advanced Dual Action Teflon® fabric protector, which allows fabric to repel and release stains. Tailored for a feminine shape, the coats feature traditional side slits, French finish inside seams and hidden inside pockets that are great for carrying handheld devices and mobile phones.

In addition to high quality lab coats, Medelita provides a line of performance women’s healthcare apparel, including clinician scrubs and nursing scrubs, which are available for purchase at www.medelita.com.

Medelita will be exhibiting at the USA Business Information Office, set up by OTEXA, E10, Hall 16. To schedule a SKYPE pre-briefing, please email joe@medelita.com or call 1-877-987-7979.

About Medelita
Medelita has one purpose: to reinvent the way women of all healthcare professions present themselves at work by offering the highest quality, best fitting, and most comfortable medical apparel available, including lab coats, women’s lab coats and women’s scrubs. Medelita caters to professional women who want their uniforms to embody the poise and confidence already displayed f r o m within. For more information, visit our website at http://www.medelita.com or call (877) 987-7979.

Via EPR Network
More Healthcare press releases